Skip to main content

Advertisement

SpringerLink
Log in

Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis

  • Psoriasis (Jaishin Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this review is to summarize the literature on the effects of biologic treatment for psoriasis on the risk of cardiovascular (CV) disease (CVD) and adverse CV outcomes.

Recent Findings

Therapy with tumor necrosis factor-alpha (TNF-α) inhibitors has been associated with reduced risk of CV events in observational studies; however, data are conflicting. Data on interleukin (IL)-17 and IL-12/23 inhibitors are limited, and primary endpoints of studies on these drugs have not been focused on CV outcomes.

Summary

Psoriasis is a chronic inflammatory skin disease that has distinct pathogenetic overlaps with that of atherosclerosis. Patients with psoriasis, in particular moderate-to-severe disease, have an increased incidence and prevalence of CV risk factors and CVD. Biologic therapies targeted for treatment of psoriasis dampen the systemic inflammation and may therefore be effective in treating not only the cutaneous manifestations of psoriasis, but may also have beneficial or detrimental CV effects depending on the particular cytokine target and mode of action. Studies on TNF-α inhibitors have suggested that these may reduce the coronary artery calcium score, improve myocardial function, and reduce the risk of adverse CV events albeit that use of these drugs may also lead to weight gain. Studies of treatment with anti-IL-12/23 agents have yielded conflicting results, but ustekinumab, the only IL-12/23 inhibitor currently approved for psoriasis, appears to be effect neutral on CV parameters. Newer drugs such as IL-17 inhibitors have not demonstrated any notable CV safety signals based on pivotal clinical trials, but long-term data from real-life studies are lacking. As new treatment modalities emerge, there is a need for well-powered long-term observational studies to firmly establish the CV safety profile of these drugs in a real-life setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. https://doi.org/10.1016/j.jaad.2008.02.039.

    Article  PubMed  Google Scholar 

  2. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53. https://doi.org/10.1016/j.jaci.2017.07.004.

    Article  CAS  PubMed  Google Scholar 

  3. Boehncke WH, Schon MP. Psoriasis. Lancet (London, England). 2015;386(9997):983–94. https://doi.org/10.1016/s0140-6736(14)61909-7.

    Article  CAS  Google Scholar 

  4. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–34. https://doi.org/10.1001/archderm.141.12.1527.

    Article  PubMed  Google Scholar 

  5. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56(4):629–34. https://doi.org/10.1016/j.jaad.2006.09.017.

    Article  PubMed  Google Scholar 

  6. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35. https://doi.org/10.1016/j.jaad.2006.08.040.

    Article  PubMed  Google Scholar 

  7. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):23–30. https://doi.org/10.1111/j.1468-3083.2009.03564.x.

    Article  PubMed  Google Scholar 

  8. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–42; discussion 42–3. https://doi.org/10.1097/HJH.0b013e32835bcce1.

    Article  CAS  PubMed  Google Scholar 

  9. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. https://doi.org/10.1001/2013.jamadermatol.406.

    Article  PubMed  Google Scholar 

  10. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. https://doi.org/10.1001/jama.296.14.1735.

    Article  CAS  PubMed  Google Scholar 

  11. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775 e1–6. https://doi.org/10.1016/j.amjmed.2011.03.028.

    Article  Google Scholar 

  12. (WHO) WHO. Global Report on Psoriasis. 2016.

  13. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–19. https://doi.org/10.1038/nri1882.

    Article  CAS  PubMed  Google Scholar 

  14. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38. https://doi.org/10.1016/j.jacc.2009.09.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273(2):197–204. https://doi.org/10.1111/j.1365-2796.2012.02593.x.

    Article  CAS  PubMed  Google Scholar 

  16. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50. https://doi.org/10.1001/archdermatol.2012.2502.

    Article  CAS  PubMed  Google Scholar 

  17. Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. https://doi.org/10.1016/j.jaad.2016.07.042.

    Article  CAS  PubMed  Google Scholar 

  18. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7(5):284–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol. 2017;44(4):363–9. https://doi.org/10.1111/1346-8138.13661.

    Article  CAS  PubMed  Google Scholar 

  20. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218–21. https://doi.org/10.1016/j.atherosclerosis.2012.06.068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–79. https://doi.org/10.1016/j.pharmthera.2007.10.001.

    Article  CAS  PubMed  Google Scholar 

  22. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210. https://doi.org/10.1159/000289205.

    Article  CAS  PubMed  Google Scholar 

  23. Ahlehoff O, Hansen PR, Gislason GH, Frydland M, Bryld LE, Elming H, et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J Eur Acad Dermatol Venereol. 2016;30(5):819–23. https://doi.org/10.1111/jdv.13152.

    Article  CAS  PubMed  Google Scholar 

  24. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22(3):341–4. https://doi.org/10.1111/j.1468-3083.2007.02429.x.

    Article  CAS  PubMed  Google Scholar 

  25. •• Hjuler KF, Bottcher M, Vestergaard C, Botker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114–21. https://doi.org/10.1001/jamadermatol.2016.1984. Experimental imaging study showing that TNF inhibition halts coronary artery disease progression in psoriasis.

    Article  PubMed  Google Scholar 

  26. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6(1):83–90. https://doi.org/10.1161/circimaging.112.975730.

    Article  PubMed  Google Scholar 

  27. Karbach S, Croxford AL, Oelze M, Schuler R, Minwegen D, Wegner J, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658–68. https://doi.org/10.1161/atvbaha.114.304108.

    Article  CAS  PubMed  Google Scholar 

  28. • Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, et al. TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Investig Dermatol. 2017;137(8):1638–45. https://doi.org/10.1016/j.jid.2017.02.977. Experimental study failing to show clinical meaningful effect of TNF inhibition of vascular inflammation in psoriasis.

    Article  CAS  PubMed  Google Scholar 

  29. Hjuler KF, Gormsen LC, Iversen L. Using FDG-PET/CT to detect vascular inflammation in patients with psoriasis: where to look? And for what?? J Investig Dermatol. 2017;137(10):2236–7. https://doi.org/10.1016/j.jid.2017.05.034.

    Article  CAS  PubMed  Google Scholar 

  30. Heredi E, Vegh J, Pogacsas L, Gaspar K, Varga J, Kincse G, et al. Subclinical cardiovascular disease and it’s improvement after long-term TNF-alpha inhibitor therapy in severe psoriatic patients. J Eur Acad Dermatol Venereol. 2016;30(9):1531–6. https://doi.org/10.1111/jdv.13649.

    Article  CAS  PubMed  Google Scholar 

  31. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731–6. https://doi.org/10.1177/039463200702000408.

    Article  CAS  PubMed  Google Scholar 

  32. Pina T, Armesto S, Lopez-Mejias R, Genre F, Ubilla B, Gonzalez-Lopez MA, et al. Anti-TNF-alpha therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7):1325–30. https://doi.org/10.1111/jdv.12814.

    Article  CAS  PubMed  Google Scholar 

  33. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525–31. https://doi.org/10.1001/jama.2011.878.

    Article  CAS  PubMed  Google Scholar 

  34. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622–7. https://doi.org/10.1111/j.1468-3083.2012.04500.x.

    Article  CAS  PubMed  Google Scholar 

  35. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–71. https://doi.org/10.1001/jama.2011.1211.

    Article  CAS  PubMed  Google Scholar 

  36. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol. 2013;68(5):863–5. https://doi.org/10.1016/j.jaad.2013.01.011.

    Article  CAS  PubMed  Google Scholar 

  37. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013;27(10):1252–61. https://doi.org/10.1111/j.1468-3083.2012.04705.x.

    CAS  PubMed  Google Scholar 

  38. Campa M, Mansouri B, Warren RB, Menter A. Erratum to: a review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther. 2016;6(2):305. https://doi.org/10.1007/s13555-016-0112-y.

    Article  Google Scholar 

  39. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–72. https://doi.org/10.1111/j.1365-2133.2011.10257.x.

    Article  CAS  PubMed  Google Scholar 

  40. Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, et al. Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875–83. https://doi.org/10.1007/s00403-015-1593-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–45. https://doi.org/10.1111/jdv.12046.

    Article  CAS  PubMed  Google Scholar 

  42. Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16(10):1002–13.

    PubMed  Google Scholar 

  43. Adami S, Cavani A, Rossi F, Girolomoni G. The role of interleukin-17A in psoriatic disease. BioDrugs Clin Immunother Biopharm Gene Ther. 2014;28(6):487–97. https://doi.org/10.1007/s40259-014-0098-x.

    CAS  Google Scholar 

  44. Eberle FC, Bruck J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis. F1000Research. 2016;5. https://doi.org/10.12688/f1000research.7927.1.

  45. Varshney P, Narasimhan A, Mittal S, Malik G, Sardana K, Saini N. Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. Sci Rep. 2016;6(1):19295. https://doi.org/10.1038/srep19295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11. https://doi.org/10.1111/bjd.12112.

    Article  CAS  PubMed  Google Scholar 

  47. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432–40 e17. https://doi.org/10.1016/j.jaad.2016.09.026.

    Article  CAS  PubMed  Google Scholar 

  48. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. https://doi.org/10.1056/NEJMoa1314258.

    Article  PubMed  Google Scholar 

  49. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98 e4. https://doi.org/10.1016/j.jaad.2016.03.024.

    Article  PubMed  Google Scholar 

  50. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, Rasmussen MK, Skov L. Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.16102.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark

    Mattias Henning, Hasan Göcker Tekin, Lone Skov & Alexander Egeberg

Authors
  1. Mattias Henning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hasan Göcker Tekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lone Skov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Egeberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Egeberg.

Ethics declarations

Conflict of Interest

Dr. Egeberg reports grants and personal fees from Lilly, grants and personal fees from Pfizer, personal fees from Novartis, personal fees from Janssen, personal fees from Samsung Bioepis, and personal fees from Galderma, outside the submitted work.

Dr. Skov reports personal fees from Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or served on Advisory Boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi. She has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma and received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and Leo Pharma, outside the submitted work.

Dr. Henning has nothing to disclose.

Dr. Tekin has nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henning, M., Tekin, H.G., Skov, L. et al. Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis. Curr Derm Rep 7, 37–42 (2018). https://doi.org/10.1007/s13671-018-0210-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-018-0210-4

Keywords

Search

Navigation